Shengjuan Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shengjuan Luo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Zheng Wang
Department of Hepatobiliary Surgery
2 shared publications- Cejun Yang
Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha 410013, China
1 shared publication - Ho
Chang Gung Memorial Hospital
1 shared publication Hong Peng
Department of Ultrasonography, The Third Xiangya Hospital of Central South University, Changsha, China
1 shared publicationJ. L. Lin
Chang Gung Memorial Hospital
1 shared publicationJ. Y. Chen
Chang Gung Memorial Hospital
1 shared publication
Latest Publications
- Open Access
- 21 June 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (11) , 3343-3350
Clinical and Imaging Characteristics of Herlyn-Werner-Wunderlich Syndrome: a Comprehensive Analysis
Purpose: To describe the clinical and imaging characteristics of Herlyn-Werner-Wunderlich syndrome (HWWS). Methods: This study presented an observational case series involving consecutive patients diagnosed with HWWS, whose medical records were retrospectively reviewed. From June 2012 to December 2022, there were a total of 85 patients with HWWS enrolled in our study. We obtained the medical history, including demographic characteristics, clinical presentation, treatment, complications, and radiologic examinations performed. Patients > 18 years of age (n = 58) were recontacted. Result: In our analysis, 27 patients were categorised as having complete obstruction, and 58 were categorised as having incomplete obstruction. The mean age at the onset of symptoms and diagnosis of complete obstruction was significantly younger than incomplete obstruction (P < 0.05). For complete obstruction, the median time between menarche and the onset of symptoms was 2.1 years, while for incomplete obstruction, it was 5.3 years. There was a significantly lower incidence of intermittent mucopurulent discharge, irregular vaginal haemorrhage, and occasional examination findings of complete obstruction than incomplete obstruction (P < 0.05). Complete obstruction was significantly associated with dysmenorrhea and pelvic endometriosis compared with incomplete obstruction (P < 0.05). Conclusions: There are distinct clinical differences between patients with complete obstruction of the hemivagina and those with incomplete obstruction. HWWS can manifest as various combinations of uterine anomalies, communications anomalies, and renal anomalies. Early recognition and treatment can avoid complications and preserve fertility. Keyswords: Herlyn-Werner-Wunderlich syndrome (HWWS); complete obstruction; incomplete obstruction; obstructed hemivagina; congenital malformation.
- 21 June 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (11) , 3343-3350
Open AccessClinical and Imaging Characteristics of Herlyn-Werner-Wunderlich Syndrome: a Comprehensive Analysis
Purpose: To describe the clinical and imaging characteristics of Herlyn-Werner-Wunderlich syndrome (HWWS). Methods: This study presented an observational case series involving consecutive patients diagnosed with HWWS, whose medical records were retrospectively reviewed. From June 2012 to December 2022, there were a total of 85 patients with HWWS enrolled in our study. We obtained the medical history, including demographic characteristics, clinical presentation, treatment, complications, and radiologic examinations performed. Patients > 18 years of age (n = 58) were recontacted. Result: In our analysis, 27 patients were categorised as having complete obstruction, and 58 were categorised as having incomplete obstruction. The mean age at the onset of symptoms and diagnosis of complete obstruction was significantly younger than incomplete obstruction (P < 0.05). For complete obstruction, the median time between menarche and the onset of symptoms was 2.1 years, while for incomplete obstruction, it was 5.3 years. There was a significantly lower incidence of intermittent mucopurulent discharge, irregular vaginal haemorrhage, and occasional examination findings of complete obstruction than incomplete obstruction (P < 0.05). Complete obstruction was significantly associated with dysmenorrhea and pelvic endometriosis compared with incomplete obstruction (P < 0.05). Conclusions: There are distinct clinical differences between patients with complete obstruction of the hemivagina and those with incomplete obstruction. HWWS can manifest as various combinations of uterine anomalies, communications anomalies, and renal anomalies. Early recognition and treatment can avoid complications and preserve fertility. Keyswords: Herlyn-Werner-Wunderlich syndrome (HWWS); complete obstruction; incomplete obstruction; obstructed hemivagina; congenital malformation.
- Open Access
- 16 May 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (32) , 17958-17966
Selective ultrasound contrast enhancement in the tumor by nanocapsules with perfluorooctylbromide: effect of PLGA–PEG proportion
We used PLGA–COOH and PLGA–PEG–COOH blended polymer material to encapsulate perfluorooctyl bromide to prepare nanocapsules (NCs) as nano-ultrasound contrast agents. The aim of this study was to assess the effect of PLGA–PEG proportion on the physical, biological and acoustic characteristics of the nanocapsules, and to develop optimal nanocapsules for selective ultrasound contrast enhancement in tumors. The weight ratio of PLGA–PEG in the formulation was 0, 25%, 50%, 75%, and 100%, and the corresponding nanocapsules were designated NCsPLGA, NCs25% PLGA–PEG, NCs50% PLGA–PEG, NCs75% PLGA–PEG and NCs100% PLGA–PEG. As the PLGA–PEG proportion increased, the diameter and bulk modulus of the NCs gradually decreased, and the originally smooth surface of NCs was roughened. NCsPLGA, NCs25% PLGA–PEG and NCs50% PLGA–PEG had regular spherical shape and relatively distinct boundaries compared with NCs75% PLGA–PEG and NCs100% PLGA–PEG, which showed heavy agglomeration. The proportion of PLGA–PEG in the formula could also change the uptake rate of NCs by RAW 264.7 cells. NCs50% PLGA–PEG and NCs75% PLGA–PEG had the lowest uptake by RAW 264.7 cells. In vitro, the ultrasonic gray values of NCs50% PLGA–PEG, NCs75% PLGA–PEG and NCs100% PLGA–PEG were obviously higher than those of NCsPLGA and NCs100% PLGA–PEG. NCsPLGA, NCs50% PLGA–PEG and NCs100% PLGA–PEG were injected into mice via the tail vein, but only NCs50% PLGA–PEG could produce persistent gray contrast enhancement in tumors after 24 h. Histological fluorescence of the tumor tissue confirmed that NCs50% PLGA–PEG and NCs100% PLGA–PEG gathered in tumor tissues. Our results indicate that the PLGA–PEG proportion in the formula is an important factor in constructing optimal nano-ultrasound contrast agents with a liquid core, and could change the nanocapsule size, surface morphology, elastic modulus, macrophage cellular uptake, and ultrasonic reflection. An appropriate PLGA–PEG proportion could help nanoparticles to achieve selective gray contrast enhancement in tumors.
- 16 May 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (32) , 17958-17966
Open AccessSelective ultrasound contrast enhancement in the tumor by nanocapsules with perfluorooctylbromide: effect of PLGA–PEG proportion
We used PLGA–COOH and PLGA–PEG–COOH blended polymer material to encapsulate perfluorooctyl bromide to prepare nanocapsules (NCs) as nano-ultrasound contrast agents. The aim of this study was to assess the effect of PLGA–PEG proportion on the physical, biological and acoustic characteristics of the nanocapsules, and to develop optimal nanocapsules for selective ultrasound contrast enhancement in tumors. The weight ratio of PLGA–PEG in the formulation was 0, 25%, 50%, 75%, and 100%, and the corresponding nanocapsules were designated NCsPLGA, NCs25% PLGA–PEG, NCs50% PLGA–PEG, NCs75% PLGA–PEG and NCs100% PLGA–PEG. As the PLGA–PEG proportion increased, the diameter and bulk modulus of the NCs gradually decreased, and the originally smooth surface of NCs was roughened. NCsPLGA, NCs25% PLGA–PEG and NCs50% PLGA–PEG had regular spherical shape and relatively distinct boundaries compared with NCs75% PLGA–PEG and NCs100% PLGA–PEG, which showed heavy agglomeration. The proportion of PLGA–PEG in the formula could also change the uptake rate of NCs by RAW 264.7 cells. NCs50% PLGA–PEG and NCs75% PLGA–PEG had the lowest uptake by RAW 264.7 cells. In vitro, the ultrasonic gray values of NCs50% PLGA–PEG, NCs75% PLGA–PEG and NCs100% PLGA–PEG were obviously higher than those of NCsPLGA and NCs100% PLGA–PEG. NCsPLGA, NCs50% PLGA–PEG and NCs100% PLGA–PEG were injected into mice via the tail vein, but only NCs50% PLGA–PEG could produce persistent gray contrast enhancement in tumors after 24 h. Histological fluorescence of the tumor tissue confirmed that NCs50% PLGA–PEG and NCs100% PLGA–PEG gathered in tumor tissues. Our results indicate that the PLGA–PEG proportion in the formula is an important factor in constructing optimal nano-ultrasound contrast agents with a liquid core, and could change the nanocapsule size, surface morphology, elastic modulus, macrophage cellular uptake, and ultrasonic reflection. An appropriate PLGA–PEG proportion could help nanoparticles to achieve selective gray contrast enhancement in tumors.
- Open Access
- 7 February 2018
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2018, 1-10
Carboxyl of Poly(D,L-lactide-co-glycolide) Nanoparticles of Perfluorooctyl Bromide for Ultrasonic Imaging of Tumor
Perfluorooctyl bromide (PFOB) enclosed nanoparticles (NPs) as ultrasonic contrasts have shown promising results in the recent years. However, NPs display poor contrast enhancement in vivo. In this work, we used the copolymers poly(lactide-co-glycolide) carboxylic acid (PLGA-COOH) and poly(lactide-co- glycolide) poly(ethylene glycol) carboxylic acid (PLGA-PEG-COOH) as a shell to encapsulate PFOB to prepare a nanoultrasonic contrast agent. The NPs were small and uniform ( nm with a polydispersity index of ) with a complete shell nuclear structure under the transmission electron microscopy (TEM). In vitro, when concentration of NPs was ≥10 mg/ml and clinical diagnostic frequency was ≥9 MHz, NPs produced intensive enhancement of ultrasonic gray-scale signals. NPs could produce stable and obvious gray enhancement with high mechanical index (MI) (MI > 0.6). In vivo, the NPs offered good ultrasound enhancement in tumor after more than 24 h and optical imaging also indicated that NPs were mainly located at tumor site. Subsequent analysis confirmed that large accumulation of fluorescence was observed in the frozen section of the tumor tissue. All these results caused the conclusion that NPs encapsulated PFOB has achieved tumor-selective imaging in vivo.- 7 February 2018
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2018, 1-10
Open AccessCarboxyl of Poly(D,L-lactide-co-glycolide) Nanoparticles of Perfluorooctyl Bromide for Ultrasonic Imaging of Tumor
Perfluorooctyl bromide (PFOB) enclosed nanoparticles (NPs) as ultrasonic contrasts have shown promising results in the recent years. However, NPs display poor contrast enhancement in vivo. In this work, we used the copolymers poly(lactide-co-glycolide) carboxylic acid (PLGA-COOH) and poly(lactide-co- glycolide) poly(ethylene glycol) carboxylic acid (PLGA-PEG-COOH) as a shell to encapsulate PFOB to prepare a nanoultrasonic contrast agent. The NPs were small and uniform ( nm with a polydispersity index of ) with a complete shell nuclear structure under the transmission electron microscopy (TEM). In vitro, when concentration of NPs was ≥10 mg/ml and clinical diagnostic frequency was ≥9 MHz, NPs produced intensive enhancement of ultrasonic gray-scale signals. NPs could produce stable and obvious gray enhancement with high mechanical index (MI) (MI > 0.6). In vivo, the NPs offered good ultrasound enhancement in tumor after more than 24 h and optical imaging also indicated that NPs were mainly located at tumor site. Subsequent analysis confirmed that large accumulation of fluorescence was observed in the frozen section of the tumor tissue. All these results caused the conclusion that NPs encapsulated PFOB has achieved tumor-selective imaging in vivo. - 1 October 2003
- Published by Springer Nature in Clinical Rheumatology
- Vol. 22 (4-5) , 295-298
Gout in systemic lupus erythematosus and overlap syndrome ? a hospital-based study
The negative association between gout and rheumatoid arthritis is widely accepted, and gout is also speculated to be rare in systemic lupus erythematosus (SLE), as only a few sporadic cases have been reported. From 1985 to 2001 we encountered 15 lupus patients at Chang-Gung Memorial Hospital, including two with lupus–scleroderma and one with lupus–scleroderma–polymyositis overlap syndrome coexisting with gout. This study retrospectively analyses the clinical and laboratory characteristics of these patients. A lower female predominance is found, and most patients developed gout after the onset of SLE, although gout preceded SLE in two cases. Measurement of serum uric acid and 24-h urine uric acid found all of the patients to be hyperuricaemic and underexcretors of uric acid. Furthermore, most of the patients (14/15) were receiving diuretics. Also, many had hypertension and serious cardiovascular diseases. Renal impairment during gouty attacks seemed to be a predisposing factor for developing end-stage renal disease. Gouty arthritis usually occurred during relative SLE inactivity, podagra was frequent, and tophi were found in a few patients. Compared with the unselected population of SLE patients, the cases studied here had a higher incidence of chronic arthritis, malar rash, haematologic disorder, photosensitivity, serositis and neurologic disorder. Renal disease in the patients sampled was frequently membranous nephropathy.
- 1 October 2003
- Published by Springer Nature in Clinical Rheumatology
- Vol. 22 (4-5) , 295-298
Gout in systemic lupus erythematosus and overlap syndrome ? a hospital-based study
The negative association between gout and rheumatoid arthritis is widely accepted, and gout is also speculated to be rare in systemic lupus erythematosus (SLE), as only a few sporadic cases have been reported. From 1985 to 2001 we encountered 15 lupus patients at Chang-Gung Memorial Hospital, including two with lupus–scleroderma and one with lupus–scleroderma–polymyositis overlap syndrome coexisting with gout. This study retrospectively analyses the clinical and laboratory characteristics of these patients. A lower female predominance is found, and most patients developed gout after the onset of SLE, although gout preceded SLE in two cases. Measurement of serum uric acid and 24-h urine uric acid found all of the patients to be hyperuricaemic and underexcretors of uric acid. Furthermore, most of the patients (14/15) were receiving diuretics. Also, many had hypertension and serious cardiovascular diseases. Renal impairment during gouty attacks seemed to be a predisposing factor for developing end-stage renal disease. Gouty arthritis usually occurred during relative SLE inactivity, podagra was frequent, and tophi were found in a few patients. Compared with the unselected population of SLE patients, the cases studied here had a higher incidence of chronic arthritis, malar rash, haematologic disorder, photosensitivity, serositis and neurologic disorder. Renal disease in the patients sampled was frequently membranous nephropathy.